Connect with us

Headlines

CooperVision Makes an Acquisition

It bought a scleral lens company.

mm

Published

on

PLEASANTON, CA — CooperVision has acquired Blanchard Contact Lenses Inc., a scleral lens company.

Financial terms of the deal were not disclosed.

“The acquisition further expands our scleral lens portfolio, extending the way we help improve the way people see each day,” said Juan Carlos Aragón, president of CooperVision’s Specialty EyeCare Division. “Its innovative products, services, technologies and people will augment what we are building with Paragon, Procornea, and Soflex. This creates even more opportunities for CooperVision to partner with eye care professionals (ECPs), and for them to meet a range of patient needs.”

Blanchard, with its network of distributors, enjoys a strong brand position in North America, Europe (including Scandinavia), Central America and South America, according to a press release from CooperVision. Its products are available in more than 20 countries.

“The new relationship with CooperVision will be instrumental in extending our reach and potential, providing access to a broad range of research, operations and commercial resources for the benefit of customers and wearers,” said Jean Blanchard, president of Blanchard Contact Lenses, who will continue to lead the organization. He has also been appointed as a member of the CooperVision Specialty EyeCare global management team.

Founded in 1986, Blanchard has operations in Sherbrooke, Quebec; and Manchester, NJ. It employs about 70 people. Like CooperVision’s other specialty businesses, it will retain its name and continue to operate as a separate organization.

Advertisement

The acquisition includes Blanchard’s U.S. and Canadian entities.

Advertisement

SPONSORED VIDEO

SPONSORED BY SAFILO

Safilo’s “American Eyes” Video Celebrates Elasta and Emozioni starring ECPs Peter Tacia and Heidi Dancer

For the third year in a row, Safilo has looked to trusted eyecare professionals to star in its American Eyes campaign for its Elasta and Emozioni collections.Their latest testimonials are from Peter Tacia, O.D. and Heidi Dancer, optician, of Alma, MI, talking about two best-selling collections: Elasta and Emozioni.

Promoted Headlines

Headlines

Ophthalmologists Hope to Undo State Law That Allows ODs to Perform Eye Surgery

They’re attempting a ballot referendum.

mm

Published

on

A movement is afoot in Arkansas to undo recently passed state legislation that allows optometrists to perform certain surgeries.

It’s being led by Safe Surgery Arkansas, a group of medical doctors, Talk Business & Politics reports. They hope to use a ballot referendum to accomplish their goal.

R. Scott Lowery, president of the Arkansas Ophthalmological Society, was quoted saying: “Every day the people of Arkansas rely on medical doctors who have the experience and training to perform medical procedures to ensure that they are getting world class healthcare in Arkansas. We are confident that when the people are heard on this issue, they will not allow individuals without medical degrees and without surgical residencies to jeopardize the precious eyesight of Arkansans.”

The legislation was signed into law in March. The procedures that it allows optometrists to perform include selective laser trabeculoplasty and Nd:YAG laser procedures, along with injections (excluding intravenous and intraocular), removal of lid lesions and chalazion incision and curettage.

Advertisement

The bill called on the Arkansas Board of Optometry to establish credentialing requirements for optometrists to perform these laser procedures, as well as require those doctors to report the outcomes of their procedures to the board.

Vicki Farmer, executive director of the Arkansas Optometry Association, was quoted noting that Arkansas legislators “overwhelmingly approved this measure during the recent session, after listening to hours of testimony and debate, and learning optometrists in other states, like Oklahoma, have been safely performing these procedures for more than 20 years.”

Read more at Talk Business & Politics

Continue Reading

Headlines

Eye Doctors Can Play a Key Role in Diagnosing Gut Disease

About 3.1 million people in the U.S. have IBD, which includes Crohn’s disease and ulcerative colitis.

mm

Published

on

Optometrists can play an important role in helping patients who have inflammatory bowel disease, the American Optometric Association reports.

Inflammatory bowel disease can cause symptoms in the eye, which ODs can detect during during comprehensive eye examinations, according to a newly released AOA Health Policy Institute brief.

“Given that comprehensive eye examinations can lead to earlier, definitive diagnosis of IBD, patient outcomes improve with earlier treatment,” AOA reports.

“The clinical manifestations of common inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis, are not restricted to the gastrointestinal tract,” according to the Health Policy Institute brief. “IBDs have impact to other organs in a significant number of patients, including the eyes in 72.1 percent of patients with IBDs.”

The brief links IBD’s inflammation to a variety of ophthalmic conditions, including:

  • Episcleritis
  • Scleritis
  • Keratoconjunctivitis sicca (dry eye)
  • Retinal edema
  • Optic neuritis (swelling of the optic nerve)
  • Extraocular muscle nerve palsies.

According to the brief, about 3.1 million people in the U.S. have IBD, which includes Crohn’s disease and ulcerative colitis.

“Evaluation of the eye should be a routine component of care in patients with IBD just as it is with similar chronic co-morbid systemic conditions like diabetes,” according to the paper.

Continue Reading

Headlines

Eye Health Firm Acquired in $800M Deal

The acquisition focuses on treatments for inherited retinal disorders.

mm

Published

on

CAMBRIDGE, MA — Biogen announced that it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company focused on treatments for inherited retinal disorders.

As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology, according to a press release.

The transaction value was about $800 million. Nightstar’s common stock will no longer be listed for trading on the Nasdaq Global Select Market.

Nightstar is developing adeno-associated virus treatment. Its lead asset is NSR-REP1 for the treatment of choroideremia, a rare degenerative, X-linked inherited retinal disorder that leads to blindness and has no approved treatments. Initially, patients with choroideremia experience poor night vision, and over time progressive visual loss leads to complete blindness.

NSR-RPGR is Nightstar’s second clinical program for the treatment of X-linked retinitis pigmentosa, which is also a rare inherited retinal disease primarily affecting males with no approved treatments. The disease leads to loss of photoreceptor cells, resulting in retinal dysfunction by adolescence and early adulthood, progressing to legal blindness when patients reach their 40s.

“Today marks a significant achievement for Biogen,” said Michel Vounatsos, Biogen’s CEO. “The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities. We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”

Continue Reading

Advertisement

Advertisement

Advertisement

Most Popular